简介：AbstractObjective:Altered bile acid transformation induces low-grade chronic inflammation and may play an important role in the pathophysiology of polycystic ovary syndrome (PCOS). Liquiritincan regulate bile acid metabolism and anti-inflammatory properties; however, limited information is available regarding its therapeutic potential in PCOS.Methods:Female C57BL/6 mice were randomly assigned into four groups (n = 6 mice/group): the control, letrozole or dehydroepiandrosterone-induced PCOS groups, PCOS + 20 mg/kg liquiritin group, and control + liquiritin groups. After 21 days of treatment, the mice were euthanized, and the associated metabolism indications were investigated. Ovarian histological examinations were performed, and serum hormone concentration was measured. The expression of key genes involved in steroid hormone synthesis, ovarian follicle development, and ovulation was assessed.Results:Liquiritin reduced fasting blood glucose levels and increased insulin sensitivity compared to the PCOS group. Liquiritin also significantly decreased serum levels of total testosterone (P < 0.001) and dehydroepiandrosterone sulfate (P < 0.05) in the PCOS group. Histomorphological inspection of ovaries from the liquiritin group revealed fewer cystic dilated follicles than in the PCOS group. Moreover, liquiritinsignificantly (P < 0.01) decreased Cyp17a1, Cyp19a1, Fshr, Hsd3b2, Runx2, and Ccn2 mRNA expression compared to letrozole-induced PCOS.Conclusion:Liquiritin may be safe and helpful in ameliorating PCOS-associated hyperandrogenemia and hyperglycemia. However, clinical trials investigating different liquiritin dosages are needed to confirm these findings.

简介：AbstractThis study aims to evaluate the biosafety awareness of laboratory staff working on pathogens detection in seven Centers for Disease Control and Prevention and support these staff's biosafety management and training. A total of 208 laboratory staff from seven provincial CDCs were chosen by stratified random sampling to undergo a self-administered questionnaire survey. The collected data were analyzed using SPSS 22.0. The overall average biosafety awareness of the CDC laboratory staff involved in pathogen detection was 82.5 points. The average biosafety awareness score was the highest in health monitoring (92.63 points) and the lowest in risk assessment and control (41.6 points). Among the seven provincial CDCs, the Guizhou Provincial Center for Disease Control and Prevention laboratory staff showed the lowest average biosafety awareness score (74.3 points). The team who worked for 5-14 years were more likely to score above the passing score (≥88 points; corrected OR 0.400, 95%CI: 0.168-0.951) than the staff with less than five years of work experience. In addition, the mid-level and junior-level staff, as well as the lower position ones were more likely to score below the passing score (<88 points; junior level and lower: corrected OR 3.473, 95%CI: 1.028-11.737; mid-level: corrected OR 2.797, 95%CI: 1.027-7.618) compared with the senior-level staff. Among the surveyed team, 66.3% identified a lack of specific funds related to work, 61.5% identified a lack of designated personnel for the laboratory biosafety management. The biosafety awareness in CDC laboratory staff involved in pathogen detection is low, especially regarding risk assessment and control. The biosafety awareness in Guizhou and Guangxi Provincial CDC laboratory staff is also low. Laboratory funding, job title, and years of experience in a laboratory influence biosafety awareness in CDC laboratory staff. The biosafety knowledge, education, and training of CDC laboratory staff involved in pathogen detection need to improve by paying attention to the content and coverage of biosafety training, exploring new training modalities, and increasing funding for activities related to biosafety in CDC.